The Predictive Role of p16 Deletion, p53 Deletion, and Polysomy 9 and 17 in Pancreatic Ductal Adenocarcinoma

EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results

(2011) Nisa Kubiliun et al.   GASTROINTESTINAL ENDOSCOPY

Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

(2011) Jennifer L. Spratlin et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chromosomal translocation t(1;9)(q24;q34) in acute lymphoblastic leukemia patient involving the ABL1 gene

(2011) Adriana Zámečníkova   LEUKEMIA RESEARCH

Major Molecular Markers in Pancreatic Ductal Adenocarcinoma and Their Roles in Screening, Diagnosis, Prognosis, and Treatment

(2011) Puneet Singh et al.   PANCREAS

Evaluation of upper urinary tract tumors by FISH in Chinese patients

(2010) Zhengfei Shan et al.   CANCER GENETICS AND CYTOGENETICS

Concomitant and successive amplifications of MYC in APL-like leukemia

(2010) Hélène Bruyère et al.   CANCER GENETICS AND CYTOGENETICS

Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy

(2010) Jesse D Martinez   Future Oncology

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

(2009) Monica M Reinholz et al.   LANCET ONCOLOGY

Molecular markers of pancreatic cancer: development and clinical relevance

(2008) Lucia C. Fry et al.   LANGENBECKS ARCHIVES OF SURGERY

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas

(2008) Simion Chiosea et al.   MODERN PATHOLOGY